Plasma YKL-40 as a biomarker for poor prognosis in patients with metastatic colorectal cancer treated with 3rd line cetuximab and irinotecan

Authors :: Benny Vittrup Jensen
Karen-Lise Garm Spindler
Christensen, Ib J.
Schou, Jakob V.
Dorte Nielsen
Anders Jakobsen
Estrid Hoegdall
Per Pfeiffer
Mette Yilmaz
Johansen, Julia S.
Source :: University of Southern Denmark, Jensen, B V, Spindler, K-L G, Christensen, I J, Schou, J V, Nielsen, D, Jakobsen, A, Hoegdall, E, Pfeiffer, P, Yilmaz, M & Johansen, J S 2016, ' Plasma YKL-40 as a biomarker for poor prognosis in patients with metastatic colorectal cancer treated with 3rd line cetuximab and irinotecan ', ESMO 2016 Congress, Copenhagen, Denmark, 07/10/2016-11/10/2016 .

Database :: OpenAIRE
Journal :: University of Southern Denmark, Jensen, B V, Spindler, K-L G, Christensen, I J, Schou, J V, Nielsen, D, Jakobsen, A, Hoegdall, E, Pfeiffer, P, Yilmaz, M & Johansen, J S 2016, ' Plasma YKL-40 as a biomarker for poor prognosis in patients with metastatic colorectal cancer treated with 3rd line cetuximab and irinotecan ', ESMO 2016 Congress, Copenhagen, Denmark, 07/10/2016-11/10/2016 .
Accession number :: edsair.dedup.wf.001..6db11992a6bcc1bedefa383f76f5de70

Tools